Trial Watch: Phase II and Phase III attrition rates 2011–2012

@article{Arrowsmith2013TrialWP,
  title={Trial Watch: Phase II and Phase III attrition rates 2011–2012},
  author={John Edmund Arrowsmith and Philip J Miller},
  journal={Nature Reviews Drug Discovery},
  year={2013},
  volume={12},
  pages={569-569}
}

Figures and Topics from this paper

Flexible Drug Approval Policies
Problem Definition: To approve a novel drug therapy, the U.S. Food and Drug Administration (FDA) requires clinical trial evidence demonstrating efficacy with 2.5% statistical significance, althoughExpand
Harnessing Human Microphysiology Systems as Key Experimental Models for Quantitative Systems Pharmacology.
TLDR
Quantitative systems pharmacology is a complementary approach to traditional, target-centric pharmacology and drug discovery and is based on an iterative application of computational and systems biology methods with multiscale experimental methods, both of which include models of ADME-Tox and disease. Expand
CNS Target Identification and Validation: Avoiding the Valley of Death or Naive Optimism?
TLDR
Previous methods for identifying and validating novel targets for CNS drug discovery are outlined, and potential new strategies that may improve the probability of success of developing novel treatments for CNS disorders are discussed. Expand
Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer
TLDR
The workshop focused on key issues in optimizing models for cancer immunotherapy research, with discussions on the strengths and weaknesses of current models, approaches to improve the predictive value of mouse models, and advances in cancer modeling that are anticipated in the near future. Expand
Novel methods for early phase clinical trials
TLDR
Bayesian sample size calculations for single-arm and randomised phase II trials with time-to-event endpoints are considered and sample sizes obtained are consistent with those currently used in practice while better accounting for available information and uncertainty in parameter estimates of the time- to-event distribution. Expand
Drug Metabolism in Early Stage Drug Discovery and Drug Development
TLDR
A novel in vitro method to detect the liver enzymes derived active metabolites against Mycobacterial tuberculosis was developed and it was found that the inhibition of 7-hydroxylation of (S)-warfarin occurs through mechanism-based inactivation. Expand
Airway and Alveoli Organoids as Valuable Research Tools in COVID-19
TLDR
Qualitative aspects of different protocols to develop airway and alveoli organoids, which have a promising perspective to further investigate COVID-19 are described. Expand
Alternative strategies in cardiac preclinical research and new clinical trial formats
TLDR
This work examines recent gold standard randomized clinical trials and presents possible modifications to increase lead candidate throughput: adaptive designs, master protocols and drug repurposing. Expand
An Effector Index to Predict Target Genes at GWAS Loci
TLDR
This work outlines a simple, understandable approach to prioritize genes at GWAS loci for functional follow-up and drug development, and provides a systematic strategy for prioritization of GWAS target genes. Expand
...
1
2
3
4
5
...